natgillin/translations-raw huggingface dataset:
In the 12 week acute phase of three clinical trials of duloxetine in patients with diabetic neuropathic pain, small but statistically significant increases in fasting blood glucose were observed in duloxetinetreated patients. 
V 12 tednov trajajoči akutni fazi treh kliničnih preskušanj duloksetina pri bolnikih z bolečino zaradi diabetične nevropatije so pri bolnikih, zdravljenih z duloksetinom, opažali majhna, a statistično značilna povišanja koncentracij glukoze v krvi na tešče.
If you forget to take YENTREVE 
Če ste pozabili vzeti zdravilo YENTREVE
The recommended dose of YENTREVE is 40 mg twice daily without regard to meals. 
Priporočeni odmerek zdravila YENTREVE je 40 mg dvakrat dnevno ne glede na obroke.
If you are depressed and/or have anxiety disorders you can sometimes have thoughts of harming or killing yourself. 
Pri bolnikih z depresijo in/ali anksiozno motnjo se občasno lahko pojavijo misli na samopoškodovanje ali samomor.
Caution is required in patients at increased risk for hyponatraemia, such as elderly, cirrhotic, or dehydrated patients or patients treated with diuretics. 
Previdnost je potrebna pri bolnicah z večjim tveganjem za hiponatremijo; denimo pri starejših, bolnicah s cirozo, dehidriranih bolnicah ali bolnicah, ki jemljejo diuretike.
• difficulty to start urinating, painful urination, needing to pass urine during the night, frequent urination, abnormal urine odour 
• težave z začetkom uriniranja, boleče uriniranje, potreba po nočnem odvajanju urina, pogosto uriniranje, nenormalen vonj urina
The co-administration of duloxetine (40 mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71 %, but does not affect the pharmacokinetics of its active 5-hydroxyl metabolite and no dosage adjustment is recommended. 
Sočasno dajanje duloksetina (40 mg dvakrat dnevno) poveča AUC tolterodina (2 mg dvakrat dnevno) v stanju dinamičnega ravnovesja za 71 %, ne vpliva pa na farmakokinetiko njegovega aktivnega 5-hidroksi presnovka, zato ne priporočamo prilagajanja odmerjanja.
Female rats receiving duloxetine before and during mating and early pregnancy had a decrease in maternal food consumption and body weight, oestrous cycle disruption, decreased live birth indices and progeny survival, and progeny growth retardation at systemic exposure levels estimated to be at the most at maximum clinical exposure (AUC). 
Podganje samice, ki so prejemale duloksetin pred in med parjenjem ter zgodnjo brejostjo, so kazale zmanjšano porabo hrane in znižanje telesne mase pri materah, motnje estrus ciklusa, zmanjšano število živorojenih in slabše preživetje potomcev ter zastoj rasti potomcev pri sistemskih izpostavitvah, ocenjenih kot največ maksimalna klinična izpostavitev (AUC).
The main ingredient of YENTREVE, duloxetine, is used in other medicines for other conditions: 
Duloksetin, glavna učinkovina zdravila YENTREVE se uporablja v drugih zdravilih za zdravljenje drugih bolezni:
Each capsule of YENTREVE contains pellets of duloxetine hydrochloride with a covering to protect them from stomach acid. 
Vsaka kapsula zdravila YENTREVE vsebuje pelete duloksetinijevega klorida z oblogo za zaščito pred želodčno kislino.
• large pupils (the dark centre of the eye), problems with eyesight, eyes feel dry 
• večje zenice (temni osrednji del očesa), motnja vida, občutek suhih oči
The pharmacokinetics of duloxetine in patients who are poor metabolisers with respect to CYP2D6 has not been specifically investigated. 
Farmakokinetike duloksetina pri bolnikih, ki imajo omejeno presnovo s CYP2D6, niso posebej preiskovali.
Antacids and H2 antagonists: Co-administration of YENTREVE with aluminium- and magnesiumcontaining antacids or with famotidine had no significant effect on the rate or extent of duloxetine absorption after administration of a 40 mg oral dose. 
Antacidi in antagonisti H2: sočasno dajanje zdravila YENTREVE z antacidi, vsebujočimi aluminij in magnezij, ali s famotidinom ni imelo pomembnega učinka na hitrost ali obseg absorpcije duloksetina po dajanju 40 mg peroralnega odmerka.
Absorption: Duloxetine is well absorbed after oral administration with a Cmax occurring 6 hours post dose. 
Absorpcija: Duloksetin se po peroralnem dajanju dobro absorbira s pojavom Cmax 6 ur po odmerjanju.
10Estimated frequency based on placebo-controlled clinical trials. 
10 Ocenjena pogostnost na podlagi kliničnih preskušanj, nadzorovanih s placebom.
Inhibitors of CYP1A2: Because CYP1A2 is involved in duloxetine metabolism, concomitant use of YENTREVE with potent inhibitors of CYP1A2 is likely to result in higher concentrations of duloxetine. 
Zaviralci CYP1A2: ker je CYP1A2 vpleten v presnovo duloksetina, je verjetno, da bo sočasna uporaba zdravila YENTREVE z močnimi zaviralci CYP1A2 povzročila višje koncentracije duloksetina.
Supra-ventricular arrhythmia, mainly atrial fibrillation6 
Srčne bolezni palpitacije tahikardija supraventrikularna aritmija, zlasti atrijska fibrilacija6
• Make sure your midwife and/or doctor knows you are on YENTREVE. 
• Svoji medicinski sestri, babici in/ali zdravniku povejte, da jemljete zdravilo YENTREVE.
Other medicines and YENTREVE 
Druga zdravila in zdravilo YENTREVE
If you have further questions on the use of this medicine, ask your doctor or pharmacist. 
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom ali s farmacevtom.
YENTREVE hard gastro-resistant capsules contain sucrose. 
YENTREVE trde gastrorezistentne kapsule vsebujejo saharozo.
Hyponatraemia has been reported when administering YENTREVE, including cases with serum sodium lower than 110 mmol/l. 
Ob dajanju zdravila YENTREVE so poročali o hiponatriemiji, vključno s primeri, ko je bila serumska koncentracija natrija pod 110 mmol/l.
If you stop taking YENTREVE 
Če ste prenehali jemati zdravilo YENREVE
The initiation of treatment with YENTREVE is contraindicated in patients with uncontrolled hypertension that could expose patients to a potential risk of hypertensive crisis (see sections 4.4 and 
Uvedba zdravljenja z zdravilom YENTREVE je kontraindicirana pri bolnicah z nenadzorovano hipertenzijo, ki lahko izpostavi bolnice možnemu tveganju za hipertenzivno krizo (glejte poglavje 4.4 in 4.8).
YENTREVE should not be used in combination with CYP1A2 inhibitors, like fluvoxamine, ciprofloxacin or enoxacin since the combination results in elevated plasma concentrations of duloxetine (see section 4.5). 
Zdravila YENTREVE ne smemo uporabljati v kombinaciji z zaviralci CYP1A2, kot so fluvoksamin, ciprofloksacin ali enoksacin, ker kombinacija povzroči povišane plazemske koncentracije duloksetina (glejte poglavje 4.5).
A meta-analysis of placebocontrolled clinical trials of antidepressant medicinal products in psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old. 
Metaanaliza s placebom nadzorovanih kliničnih preskušanj antidepresivov pri odraslih bolnikih s psihiatričnimi motnjami je pokazala, da pri bolnikih, mlajših od 25 let, pri uporabi antidepresivov obstaja večje tveganje za pojav samomorilnega vedenja kot pri uporabi placeba.
YENTREVE and Prior Continence Surgery: There are limited data that suggest that the benefits of YENTREVE are not diminished in women with stress urinary incontinence who have previously undergone continence surgery. 
Zdravilo YENTREVE in predhodno kirurško zdravljenje inkontinence: omejeni podatki kažejo, da koristi zdravila YENTREVE pri bolnicah s stresno urinsko inkontinenco, ki so bile predhodno operirane zaradi inkontinence, niso zmanjšane.
6 Estimated frequency of post-marketing surveillance reported adverse reactions; not observed in placebo-controlled clinical trials. 
6Ocenjena pogostost pojava neželenih učinkov v postmarketinških študijah; teh učinkov v s placebom kontroliranih kliničnih študijah niso opazili.
Weight decrease Weight increase Blood cholesterol increased Blood creatine 
Preiskave zmanjšanje telesne mase povečanje telesne mase zvišanje krvnega holesterola zvišanje krvne kreatininfosfokinaze zvišanje krvnega kalija
YENTREVE should not be used for children and adolescents under 18 years. 
Zdravila YENTREVE pri otrocih in mladostnikih, mlajših od 18 let, ne smemo uporabljati.
YENTREVE is a medicine to be taken by mouth to treat Stress Urinary Incontinence (SUI) in women. 
YENTREVE je zdravilo, ki ga jemljemo peroralno, za zdravljenje stresne urinske inkontinence (SUI), pri ženskah.
Your doctor will tell you if you should be taking YENTREVE. 
Vaš zdravnik vam bo povedal, če smete jemati zdravilo YENTREVE.
CNS medicinal products: Caution is advised when YENTREVE is taken in combination with other centrally acting medicinal products or substances, including alcohol and sedative medicinal products (e.g. benzodiazepines, morphinomimetics, antipsychotics, phenobarbital, sedative antihistamines). 
Zdravila CŽS: če se zdravilo YENTREVE jemlje v kombinaciji z drugimi centralno delujočimi zdravili ali snovmi, vključno z alkoholom in pomirjevali (benzodiazepini, morfinomimetiki, antipsihotiki, fenobarbitalom, sedativnimi antihistaminiki), priporočamo previdnost.
YENTREVE should be used with caution in patients with a history of mania or a diagnosis of bipolar disorder, and/or seizures. 
Zdravilo YENTREVE moramo pri bolnicah z manijo v anamnezi ali diagnozo bipolarne motnje in/ali epileptičnimi napadi uporabljati previdno.
• feeling nervous, difficulty concentrating, changes in sense of taste, poor sleep quality 
• občutek živčnosti, težave s koncentracijo, spremenjeno okušanje stvari, slaba kvaliteta spanja
• feeling of dizziness or “spinning” (vertigo) 
• občutek omotice ali vrtoglavice (vertiga)
Pharmacokinetic data on duloxetine is limited in patients with mild or moderate renal impairment. 
Farmakokinetični podatki o duloksetinu so pri bolnikih z blago ali zmerno okvarjenim delovanjem ledvic omejeni.
• passing bright red blood in your stools, inflammation of the large intestine (leading to diarrhoea) 
• svetlo rdeča kri v blatu, vnetje debelega črevesa (ki povzroča drisko)
Female mice receiving duloxetine for 2 years had an increased incidence of hepatocellular adenomas and carcinomas at the high dose only (144 mg/kg/day), but these were considered to be secondary to hepatic microsomal enzyme induction. 
Vzročni mehanizem in klinični pomen nista znana.Mišje samice, ki so prejemale duloksetin 2 leti, so imele povišano incidenco hepatocelularnih adenomov in karcinomov samo pri visokem odmerku (144 mg/kg/dan), vendar za te velja, da se pojavijo sekundarno zaradi indukcije jetrnih mikrosomskih encimov.
The antibiotic linezolid is a reversible non-selective MAOI and should not be given to patients treated with YENTREVE (see section 4.4). 
Antibiotik linezolid je reverzibilen, neselektiven MAOI in ga bolniki, zdravljeni z zdravilom YENTREVE, ne smejo prejemati (glejte poglavje 4.4).
Quality of Life: Incontinence Quality of Life (I-QOL) questionnaire scores were significantly improved in the duloxetine-treated patient group compared with the placebo-treated group (9.2 versus 5.9 score improvement, p<0.001). 
(Incontinence Quality of Life, I-QOL) so bili v skupini bolnic, zdravljenih z duloksetinom, v primerjavi s tistimi, ki so prejemale placebo, značilno izboljšani (izboljšanje števila točk 9,2 v primerjavi s 5,9, p < 0,001).
Selective serotonin reuptake inhibitors (SSRIs)/serotonin norepinephrine reuptake inhibitors (SNRIs) may cause symptoms of sexual dysfunction (see section 4.8). 
Spolna disfunkcija Selektivni zaviralci ponovnega privzema serotonina (SSRI)/zaviralci ponovnega privzema serotonina in noradrenalina (SNRI) lahko povzročijo simptome spolne disfunkcije (glejte poglavje 4.8).
Liver disease resulting in hepatic impairment (see section 5.2). 
Obolenje jeter, katerega posledica je okvarjeno delovanje jeter (glejte poglavje 5.2).
After an intravenous dose the plasma clearance of duloxetine ranges from 22 l/hr to 46 l/hr (mean of 36 l/hr). 
Po intravenskem odmerku plazemski očistek duloksetina zavzema vrednosti od 22 l/h do 46 l/h (povprečno 36 l/h).
YENTREVE must not be used in patients with severe renal impairment (creatinine clearance <30 ml/min; see section 4.3). 
Zdravila YENTREVE ne smemo uporabljati pri bolnikih s hudo okvarjenim delovanjem ledvic (očistek kreatinina < 30 ml/min, glejte poglavje 4.3).
You must wait at least 14 days after you have stopped taking an MAOI before you can take YENTREVE. 
Po prenehanju jemanja MAOI morate počakati vsaj 14 dni, preden lahko vzamete zdravilo YENTREVE.
Based on the half-life of duloxetine, at least 5 days should be allowed after stopping YENTREVE before starting an MAOI (see section 
Na podlagi razpolovnega časa duloksetina mora po prenehanju jemanja zdravila YENTREVE preteči vsaj 5 dni pred začetkom jemanja MAOI
Both cytochromes P450-2D6 and 1A2 catalyse the formation of the two major metabolites glucuronide conjugate of 4-hydroxy duloxetine and sulfate conjugate of 5-hydroxy 6-methoxy duloxetine. 
kot tudi CYP1A2 katalizirata tvorbo dveh poglavitnih presnovkov glukuronidnega konjugata 4hidroksi duloksetina in sulfatnega konjugata 5-hidroksi 6-metoksi duloksetina.
Oy Eli Lilly Finland Ab Puh/Tel: +358-(0) 9 85 45 250 
Suomi/Finland Oy Eli Lilly Finland Ab Puh/Tel: +358 (0)9 8545 250
YENTREVE must not be used in women with liver disease resulting in hepatic impairment (see sections 4.3 and 5.2). 
Zdravila YENTREVE ne smemo uporabljati pri ženskah z obolenjem jeter, katerega posledica je okvarjeno delovanje jeter (glejte poglavje 4.3 in 5.2).
The efficacy of YENTREVE has not been evaluated for longer than 3 months in placebo-controlled studies. 
Učinkovitosti zdravila YENTREVE v študijah, kontroliranih s placebom, niso vrednotili dlje kot 3 mesece.
YENTREVE 40 mg is available in packs of 28, 56, 98 and 140 hard gastro-resistant capsules and in a multipack containing 196 (2 packs of 98) hard gastro-resistant capsules. 
Zdravilo YENTREVE 40 mg je na voljo v pakiranju po 28, 56, 98 in 140 trdih gastrorezistentnih kapsul in v večjem pakiranju, ki vsebuje 196 (2 pakiranji po 98) trdih gastrorezistentnih kapsul.
Therefore YENTREVE should not be administered in combination with potent inhibitors of CYP1A2 like fluvoxamine (see section 4.3). 
Zato zdravila YENTREVE ne smemo dajati skupaj z močnimi zaviralci CYP1A2, kot je fluvoksamin (glejte poglavje 4.4).
If your doctor thinks that you no longer need YENTREVE he or she will ask you to reduce your dose over 2 weeks. 
Če bo vaš zdravnik menil, da zdravila YENTREVE ne potrebujete več, vam bo naročil/naročila, da
In pre/postnatal toxicity study in the rat, duloxetine induced adverse behavioural effects in the offspring at systemic exposure levels below maximum clinical exposure (AUC). 
V študiji pre- in postnatalne toksičnosti pri podganah je duloksetin povzročil neželene vedenjske učinke pri mladičih ob ravneh sistemskih izpostavitev, manjših od maksimalne klinične izpostavitve (AUC).
YENTREVE is indicated for women for the treatment of moderate to severe Stress Urinary Incontinence (SUI). 
YENTREVE je zdravilo, pri ženskah indicirano za zdravljenje zmerne do hude stresne urinske inkontinence (Stress Urinary Incontinence, SUI).
Hypertension3,7 Flushing 
Žilne bolezni hipertenzija3,7
Based upon in vitro studies, the circulating metabolites of duloxetine are considered pharmacologically inactive. 
Na podlagi študij in vitro veljajo presnovki duloksetina v krvnem obtoku za farmakološko nedejavne.
The most commonly reported adverse events in patients treated with YENTREVE in clinical trials in SUI and other lower urinary tract disorders were nausea, dry mouth fatigue and constipation. 
Neželeni učinki, o katerih so pri bolnicah, zdravljenih z zdravilom YENTREVE v kliničnih preskušanjih o SUI in drugih boleznih spodnjih sečil, najpogosteje poročali, so bili slabost, suha usta,
• vomiting blood, or black tarry stools (faeces), gastroenteritis, inflammation of the mouth, burping, difficulty swallowing, breaking wind, bad breath 
• več zehanja • bruhanje krvi ali črno blato, gastroenteritis, vnetje ust, riganje, težave pri požiranju, vetrovi, slab zadah
Hard gastro-resistant capsule. 
trda gastrorezistentna kapsula
EU/1/04/280/002(28 hard gastro-resistant capsules) EU/1/04/280/003 (56 hard gastro-resistant capsules) EU/1/04/280/004 (98 hard gastro-resistant capsules) EU/1/04/280/005 (140 hard gastro-resistant capsules) 
EU/1/04/280/002 (28 trdih gastrorezistentnih kapsul) EU/1/04/280/003 (56 trdih gastrorezistentnih kapsul) EU/1/04/280/004 (98 trdih gastrorezistentnih kapsul) EU/1/04/280/005 (140 trdih gastrorezistentnih kapsul)
How to take YENTREVE 
KAKO JEMATI ZDRAVILO YENTREVE
Each capsule may contain up to 37 mg sucrose. 
Ena kapsula lahko vsebuje 37 mg saharoze.
YENTREVE should not be used in combination with nonselective, irreversible monoamine oxidase inhibitors - MAOIs (see section 4.5). 
Zdravila YENTREVE ne smemo uporabljati v kombinaciji z neselektivnimi ireverzibilnimi zaviralci monoaminooksidaze - MAOI (glejte poglavje 4.5).
What YENTREVE is and what it is used for What you need to know before you take YENTREVE How to take YENTREVE 
Kaj je zdravilo YENTREVE in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo YENTREVE Kako jemati zdravilo YENTREVE
• difficulty or inability to pass urine, needing to pass more urine than normal, having a decreased urine flow 
• težave ali nezmožnost odvajanja urina, bolj pogosto odvajanje urina, slabši curek urina
• (itchy) rash, night sweats, hives, cold sweats, increased tendency to bruise 
• (srbeč) izpuščaj, nočno potenje, koprivnica, hladen znoj, povečano nagnjenje k modricam
Each capsule may contain up to 74 mg sucrose. 
Ena kapsula lahko vsebuje 74 mg saharoze.
28 hard gastro-resistant capsules 56 hard gastro-resistant capsules 98 hard gastro-resistant capsules 140 hard gastro-resistant capsules 
28 trdih gastrorezistentnih kapsul 56 trdih gastrorezistentnih kapsul 98 trdih gastrorezistentnih kapsul 140 trdih gastrorezistentnih kapsul
As the safety of duloxetine in infants is not known, the use of YENTREVE while breast-feeding is not recommended. 
Ker varnost uporabe duloksetina pri dojenčkih ni znana,
Ask your pharmacist how to throw away of medicines you no longer use. 
O načinu odstranjevanja zdravila, ki ga ne potrebujete več, se posvetujte s farmacevtom.
YENTREVE 40 mg is available in packs of 28, 56, 98, 140 and 196 (2 x 98) capsules. 
Zdravilo YENTREVE 40 mg je na voljo v pakiranjih po 28, 56, 98, 140 in 196 (2 x 98) kapsul.
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands. 
IMETNIK DOVOLJENJA ZA PROMET Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Nizozemska.
YENTREVE and Pelvic Floor Muscle Training (PFMT): During a 12-week blinded, randomised, controlled study, YENTREVE demonstrated greater reductions in IEF compared with either placebo treatment or with PFMT alone. 
Zdravilo YENTREVE in trening mišic medeničnega dna (Pelvic Floor Muscle Training, PFMT): v 12tedenski slepi, randomizirani, kontrolirani študiji je zdravilo YENTREVE pokazalo večja znižanja IEF
Edible ink: synthetic black iron oxide (E172), propylene glycol, shellac. 
Užitno črnilo: sintetični črni železov oksid (E172), propilen glikol, šelak.
Check with your doctor if you are already taking other medicines containing duloxetine. 
če že jemljete druga zdravila, ki vsebujejo duloksetin.
Capsule shell: gelatin, sodium lauryl sulfate, titanium dioxide (E171), indigo carmine (E132), red iron oxide and yellow iron oxide, edible black ink. 
Ovojnica kapsule: želatina, natrijev lavrilsulfat, titanov dioksid (E171), indigotin (E132), rdeči železov oksid in rumeni železov oksid, užitno črno črnilo.
Eli Lilly and Company Limited Tel: + 44-(0) 1256 315000 
United Kingdom Eli Lilly and Company Limited Tel: +44 (0) 1256 315999
• feeling sick (nausea), dry mouth, constipation • fatigue 
• občutek slabosti (navzea), suha usta, zaprtje
No dosage adjustment is necessary for patients with mild or moderate renal dysfunction (creatinine clearance 30 to 80 ml/min). 
Pri bolnicah z blago do zmerno okvarjenim delovanjem ledvic (očistek kreatinina 30 do 80 ml/min)
Also, you need to wait at least 5 days after you stop taking YENTREVE before you take a MAOI. 
Tudi po prenehanju jemanja zdravila YENTREVE morate počakati vsaj 5 dni, preden lahko vzamete MAOI.
Monoamine oxidase inhibitors (MAOIs): Due to the risk of serotonin syndrome, duloxetine should not be used in combination with non-selective irreversible monoamine oxidase inhibitors (MAOIs), or within at least 14 days of discontinuing treatment with an MAOI. 
Zaviralci monoaminooksidaze (MAOI): zaradi nevarnosti za serotoninski sindrom duloksetina ne smemo uporabljati v kombinaciji z neselektivnimi ireverzibilnimi zaviralci monoaminooksidaze
Mydriasis has been reported in association with duloxetine, therefore, caution should be used when prescribing duloxetine in patients with increased intraocular pressure, or those at risk of acute narrowangle glaucoma. 
V povezavi z duloksetinom so poročali o midriazi, zato je pri predpisovanju bolnicam s povišanim intraokularnim tlakom ali s tveganjem za akutni glavkom z zaprtim zakotjem potrebna previdnost.
The use of YENTREVE while breastfeeding is not recommended. 
Uporabo zdravila YENTREVE v času dojenja odsvetujemo.
The efficacy of YENTREVE is reinforced when combined with a training program called Pelvic Floor Muscle Training (PFMT). 
Učinkovitost zdravila YENTREVE je ojačana, če jo uporabljamo sočasno z izvajanjem programa, imenovanega trening mišic medeničnega dna.
• trouble sleeping, feeling agitated, less sex drive, anxiety, difficulty sleeping 
• težave s spanjem, občutek razdraženosti, manjša želja po spolnosti, anksioznost, slaba kvaliteta spanja
• muscle pain, muscle tightness, muscle spasm, contraction of the jaw muscle 
• mišična bolečina, mišična napetost, mišični krč, krčenje čeljustne mišice
No malformations were observed in another study testing a higher dose of a different salt of duloxetine. 
V drugi študiji, v kateri so preučevali višje odmerke različnih soli duloksetina, niso opazili nobenih malformacij.
The following are reasons why YENTREVE may not be suitable for you. 
Opozorila in previdnostni ukrepi Spodaj so našteti razlogi, zaradi katerih morda zdravilo YENTREVE za vas ni ustrezno.
• Stevens-Johnson syndrome (serious illness with blistering of the skin, mouth, eyes and genitals), 
• Stevens-Johnsonov sindrom (resna bolezen z mehurji na koži, ustih, očeh in genitalijah), resne alergične reakcije, ki povzročijo otekanje obraza ali grla (angioedem), občutljivost na sončno svetlobo
Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). 
Depresija je povezana z večjim tveganjem za pojav samomorilnih misli,
98 hard gastro-resistant capsules. 
98 trdih gastrorezistentnih kapsul
The 40 mg capsules are orange and blue and are printed with '40 mg' and the code ‘9545'. 
40 mg kapsule so oranžne in modre z vtisnjenim napisom ‘40 mg' in oznako ‘9545'.
Multipack: 196 (2 packs of 98 hard gastro-resistant capsules) 
FARMACEVTSKA OBLIKA IN VSEBINA Večje pakiranje: 196 (-2 pakiranji po 98 trdnih gastrorezistentnih kapsul) .
The 20 mg capsules are blue and are printed with '20 mg' and the code ‘9544'. 
20 mg kapsule so modre z vtisnjenim napisom ‘20 mg' in oznako ‘9544'.
YENTREVE contains the active substance duloxetine. 
Zdravilo YENTREVE vsebuje učinkovino duloksetin.
• dizziness, tingling feelings like pins and needles or electric shock-like feelings (particularly in the head), sleep disturbances (vivid dreams, nightmares, inability to sleep), fatigue, sleepiness, feeling restless or agitated, feeling anxious, feeling sick (nausea) or being sick (vomiting), shaking (tremor), headaches, muscle pain, feeling irritable, diarrhoea, excessive sweating or vertigo. 
• omotica, ščemenje (občutek zbadanja z iglami) ali občutki, podobni električnemu šoku (predvsem v glavi), motnje spanja (žive sanje, nočne more, nezmožnost spanja), utrujenost, zaspanost, občutek nemira ali razburjenosti, občutek strahu, slabost ali bruhanje, tresenje, glavoboli, bolečina v mišicah, občutek razdraženosti, driska, prekomerno znojenje ali vrtoglavica